NCT06791681View on ClinicalTrials.gov

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Relapsed/ Refractory Multiple Myeloma
Interventions
DRUG

ESO-T01

ESO-T01 injection is the third-generation self-inactivating lentiviral vector targeting T cells in vivo, which carries a single VHH-directed BCMA-targeted CAR.

Trial Locations (1)

430000

RECRUITING

Tongji Hospital, Tongji Medical College, Wuhan

All Listed Sponsors
collaborator

Shenzhen Pregene Biopharma Co., Ltd.

INDUSTRY

lead

Chunrui Li

OTHER